Can we wean patients with inflammatory arthritis from biological therapies?

Autoimmunity Reviews

Volumn 18, Issue 12, 2019, Pages

  Edwards, Christopher J ^a   Galeazzi, Mauro ^b   Bellinvia, Salvatore ^a,c   Ringer, Ariana ^d   Dimitroulas, Theodoros ^e   Kitas, George ^f,g  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

^c SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^e Aristotle University of Thessaloniki   (Greece)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Biological therapies; Cons; Inflammatory arthritis; Pros; Tapering

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; DISEASE ACTIVITY; DRUG SAFETY; HEALTH SERVICE; HUMAN; LYMPHOCYTE ACTIVATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SHARED DECISION MAKING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 85074519248     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2019.102399     Document Type: Review

References (69)

1. Alperi-López, M, Alonso-Castro, S, Morante-Bolado, I, Queiro-Silva, R, Riestra-Noriega, JL, Arboleya, L, et al. Biological dose tapering in daily clinical practice: a 10 year follow-up study. Reumatol Clin., 2018 Oct 11, 10.1016/j.reuma.2018.08.002 pii: S1699-258X(18)30182-7.
2. Edwards, CJ, Fautrel, B, Schulze-Koops, H, Huizinga, TWJ, Kruger, K, Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology 56:11 (2017), 1847–1856.
3. Lenert, A, Lenert, P, Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clin Rheumatol 36:1 (2017 Jan), 1–8, 10.1007/s10067-016-3490-8.
4. Singh, JA, Saag, KG, Bridges, SL, Akl, EA, Bannuru, RR, Sullivan, MC, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2015 (2016), 1–2.
5. Gossec, L, Smolen, JS, Treatment of psoriatic arthritis: management recommendations. Clin Exp Rheumatol 33:5 Suppl 93 (2015 Sep-Oct), S73–S77 [Epub 2015 Oct 15].
6. van Herwaarden, N, den Broeder, AA, Jacobs, W, van der Maas, A, Bijlsma, JW, van Vollenhoven, RF, et al. Down-titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev, 9, 2014, CD010455.
7. Henaux, S, Ruyssen-Witrand, A, Cantagrel, A, Barnetche, T, Fautrel, B, Filippi, N, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 77:4 (2018 Apr), 515–522.
8. Brocq, O, Millasseau, E, Albert, C, Grisot, C, Flory, P, Roux, CH, et al. Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76 (2009), 350–355.
9. De Stefano, R, Frati, E, De Quattro, D, Menza, L, Manganelli, S, Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 33 (2014), 707–711.
10. Sigaux, J, Bailly, F, Hajage, D, Mariette, X, Morel, J, Gandjbakhch, F, et al. Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNFblocker injections in Rheumatoid ArthritiS Study) randomised controlled trial. RMD Open, 3, 2017, e000474, 10.1136/rmdopen-2017-000474.
11. Schett, G, Emery, P, Tanaka, Y, Burmester, G, Pisetsky, DS, Naredo, E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 75 (2016), 1428–1437.
12. Arends, S, van der Veer, E, Kamps, FB, Houtman, PM, Bos, R, Bootsma, H, et al. Patient-tailored dose reduction of TNF-a blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol 33 (2015), 174–180.
13. Zavada, J, Uher, M, Sisol, K, Forejtová, Š, Jarošová, K, Mann, H, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 75 (2016), 96–102.
14. Baraliakos, X, Listing, J, Brandt, J, Zink, A, Alten, R, Burmester, G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7 (2005), 439–444.
15. Brandt, J, Khariouzov, A, Listing, J, Haibel, H, Sörensen, H, Grassnickel, L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:6 (2003), 1667–1675.
16. Cantini, F, Niccoli, L, Nannini, C, Cassarà, E, Pasquetti, P, Olivieri, I, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 47 (2008), 872–876.
17. Ye, W., Tucker, L.J., Coates, L.C., Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs, 78, 2018, 1705.
18. Lorenzin, M, Ortolan, A, de Hooge, M, Frallonardo, P, Piccoli, A, Cozzi, F, et al. Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: a single-center retrospective study. Int J Immunopathol Pharmacol 28:4 (2015), 479–487.
19. Janta, I, Martínez-Estupiñán, L, Valor, L, Montoro, M, Baniandres Rodriguez, O, Hernández Aragüés, I, et al. Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. Clin Rheumatol 34:5 (2015), 935–942.
20. Gossec, L, Smolen, JS, Ramiro, S, de Wit, M, Cutolo, M, Dougados, M, et al. European league Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:3 (2016), 499–510.
21. Huynh, DH, Boyd, TA, Etzel, CJ, Cox, V, Kremer, J, Mease, P, et al. Persistence of low disease activity after tumor necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open, 3(1), 2017, e000395.
22. Smolen, JS, Aletaha, D, Bijlsma, JW, Breedveld, FC, Boumpas, D, Burmester, G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:4 (2010 Apr), 631–637, 10.1136/ard.2009.123919.
23. Smolen, JS, Braun, J, Dougados, M, Emery, P, Fitzgerald, O, Helliwell, P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:1 (2014 Jan), 6–16, 10.1136/annrheumdis-2013-203419.
24. Hamburg, MA, Collins, FS, The path to personalized medicine. N Engl J Med 363:4 (2010 Jul 22), 301–304, 10.1056/NEJMp1006304.
25. van der Ven, M, Kuijper, TM, Gerards, AH, Tchetverikov, I, Weel, AEAM, van Zeben, D, et al. Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication?. Presented at EULAR, 2014, OP0123.
26. Marks, JL, Holroyd, CR, Dimitrov, BD, Armstrong, RD, Calogeras, A, Cooper, C, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?. Arthritis Care Res (Hoboken) 67:6 (2015 May), 746–753, 10.1002/acr.22552.
27. Smolen, JS, Nash, P, Durez, P, Hall, S, Ilivanova, E, Irazoque-Palazuelos, F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 381:9870 (2013 Mar 16), 918–929, 10.1016/S0140-6736(12)61811-X.
28. Wallis, D, Holmes, C, Holroyd, C, Sonpal, K, Zarroug, J, Adams, J, et al. Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?. Scand J Rheumatol 48:3 (2019 May), 251–252, 10.1080/03009742.2018.1533034.
29. Lau, CS, Gibofsky, A, Damjanov, N, Lula, S, Marshall, L, Jones, H, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int 37:11 (2017 Nov), 1789–1798, 10.1007/s00296-017-3780-8.
30. Ye, W, Tucker, LJ, Coates, LC, Tapering and discontinuation of biologics in patients with psoriatic arthritis with Low disease activity. Drugs. 78:16 (2018 Nov), 1705–1715, 10.1007/s40265-018-0994-3.
31. Ibrahim, F, Lorente-Cánovas, B, Doré, CJ, Bosworth, A, Ma, MH, Galloway, JB, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology (Oxford) 56:11 (2017 Nov 1), 2004–2014, 10.1093/rheumatology/kex315.
32. Emery, P, Hammoudeh, M, FitzGerald, O, Combe, B, Martin-Mola, E, Buch, MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371:19 (2014 Nov 6), 1781–1792, 10.1056/NEJMoa1316133.
33. Fautrel, B, Pham, T, Alfaiate, T, Gandjbakhch, F, Foltz, V, Morel, J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75:1 (2016 Jan), 59–67, 10.1136/annrheumdis-2014-206696.
34. den Broeder, AA, van Herwaarden, N, van der Maas, A, van den Hoogen, FH, Bijlsma, JW, van Vollenhoven, RF, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord, 14, 2013 Oct 24, 299, 10.1186/1471-2474-14-299.
35. van Herwaarden, N, van der Maas, A, Minten, MJ, van den Hoogen, FH, Kievit, W, van Vollenhoven, RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept comparedwith usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ., 350, 2015 Apr 9, h1389, 10.1136/bmj.h1389.
36. Smolen, JS, Landewé, R, Bijlsma, J, Burmester, G, Chatzidionysiou, K, Dougados, M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:6 (2017 Jun), 960–977, 10.1136/annrheumdis-2016-210715.
37. Singh, JA, Saag, KG, Bridges, SL Jr, Akl, EA, Bannuru, RR, Sullivan, MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1 (2016 Jan), 1–26, 10.1002/art.39480.
38. Lau, CS, Chia, F, Dans, L, Harrison, A, Hsieh, TY, Jain, R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22:3 (2019 Mar), 357–375, 10.1111/1756-185X.13513.
39. Bongartz, T, Sutton, AJ, Sweeting, MJ, Buchan, I, Matteson, EL, Montori, V, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 295:19 (2006 May 17), 2275–2285.
40. Mariette, X, Matucci-Cerinic, M, Pavelka, K, Taylor, P, van Vollenhoven, R, Heatley, R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:11 (2011 Nov), 1895–1904, 10.1136/ard.2010.149419.
41. Warren, FC, Abrams, KR, Sutton, AJ, Hierarchical network meta-analysis models to address sparsity of events and differing treatment classifications with regard to adverse outcomes. Stat Med 33:14 (2014 Jun 30), 2449–2466, 10.1002/sim.6131.
42. Tarp, S, Eric Furst, D, Boers, M, Luta, G, Bliddal, H, Tarp, U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford) 56:3 (2017 Mar 1), 417–425, 10.1093/rheumatology/kew442.
43. den Broeder, AA, van der Maas, A, van den Bemt, BJ, Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford) 49:10 (2010 Oct), 1801–1803, 10.1093/rheumatology/keq060.
44. Kobelt, G, Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved. Value Health 17:5 (2014 Jul), 537–544, 10.1016/j.jval.2014.04.005.
45. Fautrel, B, Verstappen, SM, Boonen, A, Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 25:4 (2011 Aug), 607–624, 10.1016/j.berh.2011.10.001.
46. Steele, FR, Personalized medicine: something old, something new. Pers Med 6:1 (2009), 1–5, 10.2217/17410541.6.1.1.
47. Treharne, GJ, Lyons, AC, Hale, ED, Douglas, KM, Kitas, GD, “Compliance” is futile but is “concordance” between rheumatology patients and health professionals attainable?. Rheumatology (Oxford) 45:1 (2006 Jan), 1–5, 10.1093/rheumatology/kei223.
48. Berry, D, Bradlow, A, Bersellini, E, Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology (Oxford) 43:7 (2004 Jul), 901–905, 10.1093/rheumatology/keh196.
49. Sokka, T, Hetland, ML, Mäkinen, H, Kautiainen, H, Hørslev-Petersen, K, Luukkainen, RK, et al. Questionnaires in standard monitoring of patients with rheumatoid arthritis group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58:9 (2008 Sep), 2642–2651, 10.1002/art.23794.
50. Cutolo, M, Kitas, GD, van Riel, PL, Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum 43:4 (2014 Feb), 479–488, 10.1016/j.semarthrit.2013.08.004.
51. Taylor, PC, Moore, A, Vasilescu, R, Alvir, J, Tarallo, M, A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:5 (2016 May), 685–695, 10.1007/s00296-015-3415-x.
52. Druce, KL, Bhattacharya, Y, Jones, GT, Macfarlane, GJ, Basu, N, Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford) 55:10 (2016 Oct), 1786–1790, 10.1093/rheumatology/kew241.
53. Zhang, H, Xu, H, Chen, S, Mao, X, The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission. J Orthop Surg Res, 13(1), 2018 Jul 3, 164, 10.1186/s13018-018-0866-2.
54. Nurmohamed, MT, Heslinga, M, Kitas, GD, Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 11:12 (2015 Dec), 693–704, 10.1038/nrrheum.2015.112.
55. Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K; BSRBR-RA Contributors Group. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford)doi: https://doi.org/10.1093/rheumatology/kez188. [Epub ahead of print].
56. de Punder, YM, Fransen, J, Kievit, W, Houtman, PM, Visser, H, van de Laar, MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 51:9 (2012 Sep), 1610–1617, 10.1093/rheumatology/kes078.
57. Olsen, IC, Lie, E, Vasilescu, R, Wallenstein, G, Strengholt, S, Kvien, TK, Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology (Oxford) 58:3 (2019 Mar 1), 481–491, 10.1093/rheumatology/key338.
58. Katchamart, W, Johnson, S, Lin, HJ, Phumethum, V, Salliot, C, Bombardier, C, Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken). 62:8 (2010 Aug), 1128–1143, 10.1002/acr.20188.
59. Rheumatoid Patient Foundation, Unmasking rheumatoid disease: the patient experience of rheumatoid arthritis. http://rheum4us.org/wp-content/uploads/2013/04/Unmasking-Rheumatoid-Disease-The-Patient-Experience-of-rheumatoid-Arthritis-White-Paper.pdf, 2013.
60. Coenen, M, Cieza, A, Stamm, TA, Amann, E, Kollerits, B, Stucki, G, Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther, 8(4), 2006, R84, 10.1186/ar1956.
61. Hope, HF, Bluett, J, Barton, A, Hyrich, KL, Cordingley, L, Verstappen, SM, Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open, 2(1), 2016 Jan 20, e000171, 10.1136/rmdopen-2015-000171.
62. Smolen, JS, Gladman, D, McNeil, HP, Mease, PJ, Sieper, J, Hojnik, M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open, 5(1), 2019 Jan 11, e000585, 10.1136/rmdopen-2017-000585.
63. Bechman, K, Clarke, BD, Rutherford, AI, Yates, M, Nikiphorou, E, Molokhia, M, et al. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford), 2019 Apr 14, 10.1093/rheumatology/kez037.
64. Galloway, JB, Hyrich, KL, Mercer, LK, Dixon, WG, Fu, B, Ustianowski, AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:1 (2011 Jan), 124–131, 10.1093/rheumatology/keq242.
65. Mercer, LK, Davies, R, Galloway, JB, Low, A, Lunt, M, Dixon, WG, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52:1 (2013 Jan), 91–98, 10.1093/rheumatology/kes350.
66. Pincus, T, Kavanaugh, A, Sokka, T, Benefit/risk of therapies for rheumatoid arthritis: underestimation of the “side effects” or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 22:5 Suppl 35 (2004 Sep-Oct), S2–11.
67. Smolen, JS, Emery, P, Ferraccioli, GF, Samborski, W, Berenbaum, F, Davies, OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 74:5 (2015 May), 843–850, 10.1136/annrheumdis-2013-204632.
68. Hashimoto, M, Furu, M, Yamamoto, W, Fujimura, T, Hara, R, Katayama, M, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther, 20(1), 2018 Aug 3, 165, 10.1186/s13075-018-1673-1.
69. Nair, KV, Tang, B, Van Den Bos, J, Zhang, V, Saseen, JJ, Naim, A, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 25:2 (2009 Feb), 303–314, 10.1185/03007990802598736.